🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Biocardia Inc (BCDA)

NASDAQ
Currency in USD
2.170
+0.010(+0.46%)
Closed
After Hours
2.100-0.070(-3.226%)
BCDA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
2.1102.200
52 wk Range
1.84010.790
Key Statistics
Edit
Prev. Close
2.17
Open
2.2
Day's Range
2.11-2.2
52 wk Range
1.84-10.79
Volume
7.35K
Average Volume (3m)
94.45K
1-Year Change
-73.41%
Book Value / Share
0.79
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BCDA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
25.000
Upside
+1,052.074%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Biocardia Inc Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Biocardia Inc SWOT Analysis


CardiAMP's Promise
Explore BioCardia's innovative cell therapy for heart failure, showing potential in reducing cardiac events and improving quality of life for patients
FDA Backing
Learn how the FDA's protocol amendment expands patient eligibility for CardiAMP HF II trial, potentially accelerating development and improving outcomes
Financial Boost
Delve into the impact of CMS reimbursement approval on BioCardia's trial costs and development timeline, enhancing the company's financial outlook
Market Opportunity
Analysts set price targets ranging from $4 to $25, reflecting the potential of BioCardia's therapy in the growing cardiovascular treatment market
Read full SWOT analysis
BCDA Full Pro Research
Institutional-Grade Stock Analysis
Understand how BCDA earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks

Biocardia Inc Earnings Call Summary for Q3/2024

  • CardiAMP Heart Failure I trial shows improved survival rates; final patient follow-up in September
  • Net loss decreased to $1.6M; expenses reduced by 53% year-over-year
  • Company aims to meet NASDAQ listing requirements; exploring non-dilutive funding options
  • FDA clearance for Morph DNA product family expected by end of current quarter
  • CEO optimistic about end of 2024 and 2025 outlook; partnerships being discussed for key platforms
Last Updated: 2024/08/15, 02:10
Read Full Transcript

Compare BCDA to Peers and Sector

Metrics to compare
BCDA
Peers
Sector
Relationship
P/E Ratio
−1.3x−6.0x−0.6x
PEG Ratio
−0.02−0.060.00
Price/Book
3.6x1.8x2.6x
Price / LTM Sales
140.1x11.5x3.2x
Upside (Analyst Target)
-290.9%45.4%
Fair Value Upside
Unlock20.9%7.7%Unlock

Analysts' Recommendations

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 25.000

(+1,052.07% Upside)

FAQ

What Is the Biocardia (BCDA) Stock Price Today?

The Biocardia stock price today is 2.17

What Stock Exchange Does Biocardia Trade On?

Biocardia is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Biocardia?

The stock symbol for Biocardia is "BCDA."

What Is the Biocardia Market Cap?

As of today, Biocardia market cap is 9.88M.

What is Biocardia Earnings Per Share?

The Biocardia EPS is -3.92.

From a Technical Analysis Perspective, Is BCDA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.